Aarhus University Seal / Aarhus Universitets segl

Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors : A nationwide case-control study. / Pedersen, Sidsel Arnspang; Johannesdottir Schmidt, Sigrun Alba; Hölmich, Lisbet Rosenkrantz; Friis, Søren; Pottegård, Anton; Gaist, David.

I: Journal of the American Academy of Dermatology, Bind 80, Nr. 2, 01.02.2019, s. 460-465.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Pedersen, SA, Johannesdottir Schmidt, SA, Hölmich, LR, Friis, S, Pottegård, A & Gaist, D 2019, 'Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study', Journal of the American Academy of Dermatology, bind 80, nr. 2, s. 460-465. https://doi.org/10.1016/j.jaad.2018.06.014

APA

Pedersen, S. A., Johannesdottir Schmidt, S. A., Hölmich, L. R., Friis, S., Pottegård, A., & Gaist, D. (2019). Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study. Journal of the American Academy of Dermatology, 80(2), 460-465. https://doi.org/10.1016/j.jaad.2018.06.014

CBE

MLA

Vancouver

Pedersen SA, Johannesdottir Schmidt SA, Hölmich LR, Friis S, Pottegård A, Gaist D. Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study. Journal of the American Academy of Dermatology. 2019 feb 1;80(2):460-465. https://doi.org/10.1016/j.jaad.2018.06.014

Author

Pedersen, Sidsel Arnspang ; Johannesdottir Schmidt, Sigrun Alba ; Hölmich, Lisbet Rosenkrantz ; Friis, Søren ; Pottegård, Anton ; Gaist, David. / Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors : A nationwide case-control study. I: Journal of the American Academy of Dermatology. 2019 ; Bind 80, Nr. 2. s. 460-465.

Bibtex

@article{7f776d9c73784bb7842caeb91452c9fb,
title = "Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study",
abstract = "Background: Hydrochlorothiazide use has been associated with markedly increased risk for squamous cell carcinoma. No previous studies have investigated the association between hydrochlorothiazide use and the risk for Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST). Objective: To examine the association between hydrochlorothiazide use and the risk for MCC and MAST. Methods: Using Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched the cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated the odds ratios (ORs) and confidence intervals (CIs) associated with cumulative use of hydrochlorothiazide. Results: The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of hydrochlorothiazide was 2.3 (95{\%} CI 1.1-4.8) and 3.6 (95{\%} CI 1.9-7.0), respectively, which increased to 3.3 (95{\%} CI 1.3-8.3) and 5.6 (95{\%} CI 2.4-13.3), respectively, with highest use (≥100,000 mg). We found no increased risk for these tumors in analyses of drugs with similar indications as hydrochlorothiazide, except there was a tendency toward an increased risk for MCC associated with the use of furosemide (OR 1.9, 95{\%} CI 0.9-4.0). Limitations: No data on sun exposure was available. Conclusion: Hydrochlorothiazide use is associated with an increased risk for MCC and MAST.",
keywords = "antihypertensives, epidemiology, hydrochlorothiazide, malignant adnexal skin tumors, Merkel cell carcinoma, pharmacology, skin cancer",
author = "Pedersen, {Sidsel Arnspang} and {Johannesdottir Schmidt}, {Sigrun Alba} and H{\"o}lmich, {Lisbet Rosenkrantz} and S{\o}ren Friis and Anton Potteg{\aa}rd and David Gaist",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.jaad.2018.06.014",
language = "English",
volume = "80",
pages = "460--465",
journal = "American Academy of Dermatology. Journal",
issn = "0190-9622",
publisher = "Mosby, Inc",
number = "2",

}

RIS

TY - JOUR

T1 - Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors

T2 - A nationwide case-control study

AU - Pedersen, Sidsel Arnspang

AU - Johannesdottir Schmidt, Sigrun Alba

AU - Hölmich, Lisbet Rosenkrantz

AU - Friis, Søren

AU - Pottegård, Anton

AU - Gaist, David

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Background: Hydrochlorothiazide use has been associated with markedly increased risk for squamous cell carcinoma. No previous studies have investigated the association between hydrochlorothiazide use and the risk for Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST). Objective: To examine the association between hydrochlorothiazide use and the risk for MCC and MAST. Methods: Using Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched the cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated the odds ratios (ORs) and confidence intervals (CIs) associated with cumulative use of hydrochlorothiazide. Results: The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of hydrochlorothiazide was 2.3 (95% CI 1.1-4.8) and 3.6 (95% CI 1.9-7.0), respectively, which increased to 3.3 (95% CI 1.3-8.3) and 5.6 (95% CI 2.4-13.3), respectively, with highest use (≥100,000 mg). We found no increased risk for these tumors in analyses of drugs with similar indications as hydrochlorothiazide, except there was a tendency toward an increased risk for MCC associated with the use of furosemide (OR 1.9, 95% CI 0.9-4.0). Limitations: No data on sun exposure was available. Conclusion: Hydrochlorothiazide use is associated with an increased risk for MCC and MAST.

AB - Background: Hydrochlorothiazide use has been associated with markedly increased risk for squamous cell carcinoma. No previous studies have investigated the association between hydrochlorothiazide use and the risk for Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST). Objective: To examine the association between hydrochlorothiazide use and the risk for MCC and MAST. Methods: Using Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched the cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated the odds ratios (ORs) and confidence intervals (CIs) associated with cumulative use of hydrochlorothiazide. Results: The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of hydrochlorothiazide was 2.3 (95% CI 1.1-4.8) and 3.6 (95% CI 1.9-7.0), respectively, which increased to 3.3 (95% CI 1.3-8.3) and 5.6 (95% CI 2.4-13.3), respectively, with highest use (≥100,000 mg). We found no increased risk for these tumors in analyses of drugs with similar indications as hydrochlorothiazide, except there was a tendency toward an increased risk for MCC associated with the use of furosemide (OR 1.9, 95% CI 0.9-4.0). Limitations: No data on sun exposure was available. Conclusion: Hydrochlorothiazide use is associated with an increased risk for MCC and MAST.

KW - antihypertensives

KW - epidemiology

KW - hydrochlorothiazide

KW - malignant adnexal skin tumors

KW - Merkel cell carcinoma

KW - pharmacology

KW - skin cancer

UR - http://www.scopus.com/inward/record.url?scp=85054534361&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2018.06.014

DO - 10.1016/j.jaad.2018.06.014

M3 - Journal article

VL - 80

SP - 460

EP - 465

JO - American Academy of Dermatology. Journal

JF - American Academy of Dermatology. Journal

SN - 0190-9622

IS - 2

ER -